Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells

Journal of Drug Targeting

Volumn 22, Issue 5, 2014, Pages 428-438

  Peng, Jianqing ^a   Qi, Xiaole ^a   Chen, Yi ^a   Ma, Ning ^a   Zhang, Ziwei ^a   Xing, Jiaxu ^a   Zhu, Xuehua ^a   Li, Zhengrong ^b   Wu, Zhenghong ^a,c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Yangtze River Pharmaceutical Group   (China)

Author keywords

Methotrexate; Octreotide; Polyamidoamine; Receptor mediated endocytosis; Tumor targeting

Indexed keywords

DENDRIMER; FLUORESCEIN ISOTHIOCYANATE; METHOTREXATE; NANOPARTICLE; OCTREOTIDE; POLYAMIDOAMINE; SOMATOSTATIN RECEPTOR; ANTINEOPLASTIC ANTIMETABOLITE; DRUG CARRIER; PAMAM STARBURST;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ENCAPSULATION; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG TARGETING; GENE OVEREXPRESSION; IN VITRO STUDY; MALE; MCF 7 CELL LINE; MEAN RESIDENCE TIME; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RADIATION DETECTION; RAT; TUMOR CELL; ANIMAL; BIOSYNTHESIS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; ENDOCYTOSIS; HUMAN; PARTICLE SIZE; SPRAGUE DAWLEY RAT; SURFACE PROPERTY; SYNTHESIS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; DENDRIMERS; DRUG CARRIERS; DRUG LIBERATION; ENDOCYTOSIS; HUMANS; MALE; MCF-7 CELLS; METHOTREXATE; MOLECULAR STRUCTURE; NANOPARTICLES; OCTREOTIDE; PARTICLE SIZE; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; SURFACE PROPERTIES;

EID: 84901064033     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.879386     Document Type: Article

References (37)

1. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005;10:35-43
2. Shukla R, Thomas TP, Peters J, et al. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun 2005;46:5739-41
3. Yiyun C, Tongwen X. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem 2005; 40:1188-92
4. Svenson S, Tomalia DA. Dendrimers in biomedical applications- reflections on the field. Adv Drug Deliv Rev 2012;57:2106-29
5. Bhadra D, Bhadra S, Jain S, Jain N. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003;257: 111-24
6. Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci 2008;97:123-43
7. Jiang YY, Tang GT, Zhang LH, et al. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. J Drug Target 2010;18:389-403
8. Zhang L, Zhu S, Qian L, et al. RGD-modified PEG-PAMAM- DOX conjugates: in vitro and in vivo studies for glioma. Eur J Pharm Biopharm 2011;79:232-40
9. Ly TU, Tran NQ, Hoang TKD, et al. Pegylated dendrimer and its effect in fluorouracil loading and release for enhancing antitumor activity. J Biomed Nanotechnol 2013;9:213-20
10. Weckbecker G, Lewis I, Albert R, et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003;2:999-1017
11. Pyronnet S, Bousquet C, Najib S, et al. Antitumor effects of somatostatin. Mol Cell Endocrinol 2008;286:230-7
12. O sapay G, Prokai L, Kim H-S, et al. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. J Med Chem 1997;40:2241-51
13. Niu J, Huang A, Xiao Y, et al. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the selfassembly supramolecular nanocarrier. J Drug Target 2013;21: 415-26
14. Su Z, Shi Y, Xiao Y, et al. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization. Int J Pharm 2013; 447:281-92
15. Abou DS, Thorek DL, Ramos NN, et al. 89Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer. Pharm Res 2013;30:878-88
16. Zou A, Chen Y, Huo M, et al. In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery. J Pharm Sci 2013;102:126-35
17. Cuntz MC, Levine EA, O'Dorisio TM, et al. Intraoperative gamma detection of 125I-lanreotide in women with primary breast cancer. Ann Surg Oncol 1999;6:367-72
18. Zhao L, Wu Q, Cheng Y, et al. High-throughput screening of dendrimer-binding drugs. J Am Chem Soc 2010;132:13182-4
19. Maingi V, Kumar MVS, Maiti PK. PAMAM dendrimer-drug interactions: effect of pH on the binding and release pattern. J Phys Chem B 2012;116:4370-6
20. Zhang J, Jin W, Wang X, et al. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm 2010; 7:1159-68
21. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7
22. Yang W, Cheng Y, Xu T, et al. Targeting cancer cells with biotin- dendrimer conjugates. Eur J Med Chem 2009;44:862-8
23. Denora N, Laquintana V, Lopalco A, et al. In vitro targeting and imaging the translocator protein TSPO 18-kDa through G (4)- PAMAM-FITC labeled dendrimer. J Control Release 2013;172: 1111-25
24. Singhai A, Jain S, Jain N. Evaluation of an aqueous injection of ketoprofen. Pharmazie 1997;52:149-51
25. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly (ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem 2000;11:910-7
26. Utreja S, Khopade A, Jain N. Lipoprotein-mimicking biovectorized systems for methotrexate delivery. Pharm Acta Helv 1999;73: 275-9
27. Lim S-J, Kim C-K. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 2002;243:135-46
28. D'Emanuele A, Attwood D. Dendrimer-drug interactions. Adv Drug Deliv Rev 2005;57:2147-62
29. Cao J, Zhang H, Wang Y, et al. Investigation on the interaction behavior between curcumin and PAMAM dendrimer by spectral and docking studies. Spectrochim Acta A Mol Biomol Spectrosc 2013;108:251-5
30. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30:592-9
31. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 2009;6: 1041-51
32. Pan G, Lemmouchi Y, Akala EO, Bakare O. Studies on PEGylated and drug-loaded PAMAM dendrimers. J Bioact Compat Polym 2005;20:113-28
33. Liu Y, Bryantsev VS, Diallo MS, Goddard III WA. PAMAM dendrimers undergo pH responsive conformational changes without swelling. J Am Chem Soc 2009;131:2798-9
34. Han L, Huang R, Liu S, et al. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm 2010;7:2156-65
35. Zou A, Huo M, Zhang Y, et al. Octreotide-modified N-octyl-O, Ncarboxymethyl chitosan micelles as potential carriers for targeted antitumor drug delivery. J Pharm Sci 2012;101:627-40
36. Barragán F, Carrion-Salip D, Gomez-Pinto I, et al. Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes. Bioconjug Chem 2012;23:1838-55
37. Huo M, Zou A, Yao C, et al. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 2012;33:6393-407